Drug intelligence / Profile preview

DW6015 (Dongwha Pharmaceutical Co., Ltd.)

Development stage: Unknown
Lead developer: Dongwha Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**DW6015** is a Dong-Wha Pharmaceutical investigational extended-release fixed-dose combination for **type 2 diabetes mellitus**. The program reformulates two undisclosed diabetes drug active ingredients from an immediate-release presentation into an extended-release product. The individual components, molecular targets, dosage form, and detailed pharmacologic mechanism have not been publicly disclosed.

Beyond the preview

Go deeper on DW6015 (Dongwha Pharmaceutical Co., Ltd.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW6015 (Dongwha Pharmaceutical Co., Ltd.).

Explore the full profile